Allergen‐Encapsulating Nanoparticles Reprogram Pathogenic Allergen‐Specific Th2 Cells to Suppress Food Allergy

Abstract

AbstractFood allergy is a prevalent, potentially deadly disease caused by inadvertent sensitization to benign food antigens. Pathogenic Th2 cells are a major driver for disease, and allergen‐specific immunotherapies (AIT) aim to increase the allergen threshold required to elicit severe allergic symptoms. However, the majority of AIT approaches require lengthy treatments and convey transient disease suppression, likely due to insufficient targeting of pathogenic Th2 responses. Here, the ability of allergen‐encapsulating nanoparticles to directly suppress pathogenic Th2 responses and reactivity is investigated in a mouse model of food allergy. NPs associate with pro‐tolerogenic antigen presenting cells, provoking accumulation of antigen‐specific, functionally suppressive regulatory T cells in the small intestine lamina propria. Two intravenous doses of allergen encapsulated in poly(lactide‐co‐glycolide) nanoparticles (NPs) significantly reduces oral food challenge (OFC)‐induced anaphylaxis. Importantly, NP treatment alters the fates of pathogenic allergen‐specific Th2 cells, reprogramming these cells toward CD25+FoxP3+ regulatory and CD73+FR4+ anergic phenotypes. NP‐mediated reductions in the frequency of effector cells in the gut and mast cell degranulation following OFC are also demonstrated. These studies reveal mechanisms by which an allergen‐encapsulating NP therapy and, more broadly, allergen‐specific immunotherapies, can rapidly attenuate allergic responses by targeting pathogenic Th2 cells.